Is Ibogaine Legal in France?

France is worth reading closely because it did something most countries did not. It banned the plant by name, twice over, and it did so having previously sold it.

What the text actually says

The operative wording is one sentence, and it repays being read rather than summarised. Added to annexe IV of the order of 22 February 1990:

Tabernanthe iboga, Tabernanthe manii, ibogaïne, ses isomères, esters, éthers et leurs sels qu’ils soient d’origine naturelle ou synthétique ainsi que toutes préparations qui en contiennent.

Three things follow from that sentence.

It bans a plant, not just a molecule. Most jurisdictions schedule ibogaine and leave the botanical question unanswered, which is why so many of these pages have to explain that the root bark occupies a different legal position from the alkaloid. France closed that gap in 2007.

It names the species twice. Tabernanthe manii is a synonym folded into Tabernanthe iboga, so the entry covers the same plant under two names. That is not sloppiness. It is what you write when you want the listing to survive a taxonomic argument, and the botanical profile sets out why the synonym mattered: the pharmaceutical product France itself once sold was described as an extract of Tabernanthe manii.

It reaches preparations. Not the substance alone but anything containing it, of natural or synthetic origin. There is no product left outside.

It is still the law

The consolidated annexe carries the same wording today that it was given in 2007, in a version last consolidated on 23 May 2021.

That matters because a scheduling decision from nearly twenty years ago is exactly the sort of thing that gets quietly superseded, and here it has not been. France has amended this annexe repeatedly since. The iboga entry has not moved.

How it got there

The order was made by the minister of health on 12 March 2007 and published in the Journal officiel on 25 March. Its recitals cite the opinion of the national commission on narcotics and psychotropics, given on 19 December 2006, and the French medicines agency of the day.

Before the ban, France sold it

This is the part that makes the French position unlike anyone else’s.

A product made from an iboga extract was sold commercially in France from the late 1930s, marketed against fatigue rather than as a psychoactive, and withdrawn in the 1960s. What ibogaine is covers what is documented about it and what is not, including two peer-reviewed sources that disagree about its strength.

So the sequence runs: sold across the counter for about thirty years, withdrawn, then forty years later the plant it came from is listed as a narcotic under both its botanical names. Nothing about the plant changed in between.

The one case that reached the highest court

In a decision of 23 March 2011, the criminal chamber of the Cour de cassation dealt with the death of a man during an initiatory ceremony.

The prosecution was for administering harmful substances causing death, and for manslaughter. The investigating chamber had already dismissed the case, finding no criminal intent and holding that the causal link between ibogaine and a death by drowning was not demonstrated, given the man’s cardiac history. The Cour de cassation rejected the appeals against that dismissal.

What this means in practice

France sits with the strictest group. There is no prescription route of the kind Canada or South Africa maintain, because the listing covers preparations and not merely the substance. There is no unscheduled space of the kind Germany leaves open for possession.

Anyone reading this from France should also read what buying it online involves, because the combination of a total ban and an unregulated supply is the one that produces the substitution cases.